Quidel Corporation (QDEL): Price and Financial Metrics

Quidel Corporation (QDEL): $138.15

-3.32 (-2.35%)

POWR Rating

Component Grades














  • QDEL scores best on the Value dimension, with a Value rank ahead of 98.18% of US stocks.
  • QDEL's strongest trending metric is Sentiment; it's been moving down over the last 31 weeks.
  • QDEL ranks lowest in Sentiment; there it ranks in the 2nd percentile.

QDEL Stock Summary

  • With a one year PEG ratio of 0.65, Quidel Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.3% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Quidel Corp is reporting a growth rate of 987.22%; that's higher than 97.8% of US stocks.
  • Revenue growth over the past 12 months for Quidel Corp comes in at 231.63%, a number that bests 97.01% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to QDEL, based on their financial statements, market capitalization, and price volatility, are SHYF, NTGR, SMED, EBS, and REZI.
  • QDEL's SEC filings can be seen here. And to visit Quidel Corp's official web site, go to www.quidel.com.

QDEL Valuation Summary

  • In comparison to the median Healthcare stock, QDEL's EV/EBIT ratio is 83.15% lower, now standing at 4.5.
  • Over the past 243 months, QDEL's price/earnings ratio has gone up 24.4.
  • Over the past 243 months, QDEL's price/sales ratio has gone up 1.6.

Below are key valuation metrics over time for QDEL.

Stock Date P/S P/B P/E EV/EBIT
QDEL 2015-08-24 3.4 3.0 -191.2 375.9
QDEL 2015-07-31 3.5 3.0 -193.2 380.1
QDEL 2009-07-17 4.4 4.2 60.6 33.9
QDEL 2006-07-24 2.9 3.0 20.4 17.2
QDEL 2006-02-10 3.5 4.0 -15.6 -22.1
QDEL 2004-03-31 2.2 2.3 10.5 16.7

QDEL Growth Metrics

  • Its 5 year price growth rate is now at 652.35%.
  • Its 3 year net cashflow from operations growth rate is now at 4468.96%.
  • Its 5 year revenue growth rate is now at 171.84%.
QDEL's revenue has moved up $1,647,379,000 over the prior 49 months.

The table below shows QDEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 1,862.353 1,154.04 948.134
2020-12-31 1,661.668 629.763 810.287
2020-09-30 1,004.643 238.356 370.783
2020-06-30 655.077 181.231 154.696
2020-03-31 561.575 162.768 88.314
2019-12-31 534.89 134.485 72.921

QDEL Price Target

For more insight on analysts targets of QDEL, see our QDEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $146.50 Average Broker Recommendation 1.75 (Moderate Buy)

QDEL Stock Price Chart Interactive Chart >

Price chart for QDEL

QDEL Price/Volume Stats

Current price $138.15 52-week high $306.72
Prev. close $141.47 52-week low $103.31
Day low $136.78 Volume 185,449
Day high $142.56 Avg. volume 891,312
50-day MA $122.44 Dividend yield N/A
200-day MA $165.94 Market Cap 5.88B

Quidel Corporation (QDEL) Company Bio

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.

QDEL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$138.15$3214.92 2672%

Below please find a table outlining a discounted cash flow forecast for QDEL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quidel Corp ranked in the 94th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 2685.5%. The most interesting components of our discounted cash flow analysis for Quidel Corp ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 132.91; that's higher than 93.19% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 12.72% of the free cash flow producing stocks we're observing.
  • QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 51.72% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

MNKKQ, PCYN, AMEH, GRFS, and FVE can be thought of as valuation peers to QDEL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

QDEL Latest News Stream

Event/Time News Detail
Loading, please wait...

QDEL Latest Social Stream

Loading social stream, please wait...

View Full QDEL Social Stream

Latest QDEL News From Around the Web

Below are the latest news stories about Quidel Corp that investors may wish to consider to help them evaluate QDEL as an investment opportunity.

Earnings Preview: Quidel (QDEL) Q2 Earnings Expected to Decline

Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

3 Reasons I Gave Up on Quidel

Quidel (NASDAQ: QDEL) is a testing company that's been experiencing tremendous sales growth over the past year, largely because of the popularity of its COVID-19 tests amid the pandemic. Shares are down 17% year to date (while the S&P 500 is up 18%), and it's possible that Quidel's stock could fall even lower before the year is over. One of the reasons I was bullish on the healthcare stock was the potential for Quidel to play a major role in testing for companies and schools as they open back up.

Yahoo | July 28, 2021

Beckman Coulter to Distribute BNP Cardiac Assay to Customers

BREA, Calif., July 26, 2021 /PRNewswire/ -- Beckman Coulter, a global clinical diagnostics leader, today announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman

PR Newswire | July 26, 2021

Quidel Announces Agreement With Beckman Coulter That Terminates Ongoing Litigation and Transitions BNP Business to Beckman Coulter

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its entry into agreements with Beckman Coulter resolving the ongoing litigation with Beckman Coulter and providing for the transition of the BNP Business to Beckman Coulter. Under these agreements, Beckman Coulter will pay Quidel cash payments of between $70 million and $75 million per year th

Business Wire | July 26, 2021

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Sekisui Diagnostics, Quidel, Abbott Laboratories, Roche, The

This report studies the Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Helicobacter Pylori (H-Pylori) Non-Invasive Testing []

Jumbo News | July 25, 2021

Read More 'QDEL' Stories Here

QDEL Price Returns

1-mo 10.26%
3-mo 25.58%
6-mo -41.67%
1-year -51.09%
3-year 94.93%
5-year 500.13%
YTD -23.10%
2020 139.44%
2019 53.69%
2018 12.62%
2017 102.38%
2016 1.04%

Continue Researching QDEL

Here are a few links from around the web to help you further your research on Quidel Corp's stock as an investment opportunity:

Quidel Corp (QDEL) Stock Price | Nasdaq
Quidel Corp (QDEL) Stock Quote, History and News - Yahoo Finance
Quidel Corp (QDEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7817 seconds.